Search results
Showing 871 to 885 of 1254 results for criteria
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.
Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
Pemetrexed for the treatment of non-small-cell lung cancer (TA124)
Evidence-based recommendations on pemetrexed for treating non-small-cell lung cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .
Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)
Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).
Digital self-help for eating disorders: early value assessment (HTG768)
Early value assessment (EVA) guidance on digital self-help for eating disorders.
Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)
Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
Evidence-based recommendations on enzalutamide (Xtandi) for treating hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on ruxolitinib (Jakavi) for treating acute graft versus host disease that has an inadequate response to corticosteroids in people 12 years and over.
Show all sections
Evidence-based recommendations on enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable.